Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
Eli Lilly (LLY) reported Q3 2026 revenue of $24.4B, up 39%, driven by Mounjaro and Zepbound. EPS rose 16% to $7.22. The company raised full-year revenue guidance to $91.0B-$92.0B and adjusted EPS guidance to $35.00-$36.00. Regulatory progress included FDA approvals for several drugs. Lilly also completed acquisitions of AtaiBeckley and Merida Biosciences.
How this was made
The 30-second read
Why it matters
Traders can update positioning based on the explicit full-year guidance raise and the breadth of FDA approvals, while monitoring how acquired IPR&D charges affect GAAP and non-GAAP EPS comparability.
Market read
A primary earnings-and-guidance update with explicit numerical raises and multiple FDA approvals, likely driving near-term repricing of 2026 expectations.
What to watch
Realized price declines (notably Zepbound and international) and the tax impact of nondeductible acquired IPR&D could limit upside if reimbursement or pricing pressure re-accelerates.
Background
Eli Lilly’s Q3 2026 release combines a major demand-driven revenue growth story (Mounjaro and Zepbound) with portfolio-wide regulatory progress and guidance increases.
Ticker impact
Lilly reported Q3 2026 results and raised full-year revenue guidance midpoint by $5.5B, alongside FDA approvals across its portfolio.
Likely upward bias as the market prices in stronger 2026 demand and regulatory momentum, partially offset by higher IPR&D-driven EPS headwinds.
The article is a primary earnings-and-guidance release with explicit numerical upgrades and new regulatory approvals, both direct drivers of near-term expectations.
Market effects
Reinforces GLP-1 and broader obesity-care demand durability and supports sentiment for large-cap pharma execution and regulatory throughput.
US FDA approval headlines can lift US-listed pharma sentiment and read-across to obesity and oncology peers.
Global revenue growth and non-US reimbursement dynamics (e.g., NRDL inclusion) highlight ongoing international scaling for metabolic and specialty franchises.
Counterpoint
EPS guidance is updated but the company also highlights large acquired IPR&D charges, which can make the earnings quality less durable than revenue growth suggests.
Key entities
- companyEli Lilly and Company
Reported Q3 2026 financial results, raised 2026 guidance, and cited multiple FDA approvals and pipeline readouts.
- productMounjaro
Q3 2026 revenue grew 65% to $10.7B, driving much of the quarter’s growth.
- productZepbound
Q3 2026 revenue grew 48% to $5.3B, with realized price pressure partially offset by demand.
- regulatoryFDA approvals
Included cardiovascular-risk reduction for Mounjaro, Onswik insulin approval, and oncology/hematology label expansions.
- business developmentAtaiBeckley and Merida Biosciences
Completed acquisitions to advance therapies in mental health and autoimmune/allergic diseases.
